Wednesday, November 15, 2017 10:07:01 PM
Not old news. Insys was willing to sell a Painkiller 100x more powerful than standard opiod to people with back pain. The fact they didn't think it was marketable says something. Insys has No morals at all
Instead of Negotiating with ElSohly and taking what turned out to be NB1222 to clinical trials immediately, they chose to spend More money and More Time developing Syndros. This from the Company who's only concern the last 5 years was How much fentanyl they could sell and how fast they could do it.
Short-term Profit-blinded bottom of the barrel people. But they still said it was a no go
It only gets worse from Here
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM